Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer.

Internal medicine (Tokyo, Japan) - 1 Jun 2022

Sakumura Miho, Ando Takayuki, Ueda-Consolvo Tomoko, Motoo Iori, Mihara Hiroshi, Kajiura Shinya, Teramoto Akira, Nanjo Sohachi, Fujinami Haruka, Yasuda Ichiro

Abstract excerpt

We herein report a 73-year-old woman with BRAF V600E-mutated colon cancer treated with encorafenib plus cetuximab with binimetinib as standard salvage therapy for patients with advanced colorectal cancer. She developed bilateral serous retinal detachment the next day, and the regimen was discontinued, resulting in complete resolution by the third day. Doublet therapy without binimetinib was initiated along with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Intercellular Signaling Peptides and Proteins

Share to Mitogens

Share to Proto-Oncogene Proteins B-raf

Share to Retinal Detachment

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34707053
DOI: 10.2169/internalmedicine.8439-21
PMCID: PMC9259315

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer.PMID 34707053Read ↗

[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].Semantic proximity Read ↗

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerSemantic proximity Read ↗

[Protein kinase inhibitors can induce retinopathy].Semantic proximity Read ↗

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study.Semantic proximity Read ↗

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.Semantic proximity Read ↗

[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

[A Case of BRAF Mutant Cecal Cancer Treated with Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.Semantic proximity Read ↗

Encorafenib and Binimetinib: First Global Approvals.Semantic proximity Read ↗

Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.Semantic proximity Read ↗

Management of Bilateral Diffuse Uveal Melanocytic Proliferation (BDUMP) - A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.